Alessandra Michelucci, Flavia Manzo Margiotta, Giammarco Granieri, Giorgia Salvia, Cristian Fidanzi, Matteo Bevilacqua, Salvatore Panduri, Marco Romanelli, Valentina Dini
Pyoderma gangrenosum (PG) is a neutrophilic dermatosis that is challenging to diagnose and treat. Clinicians frequently use fast-acting corticosteroids, which are subsequently combined with slower-acting immunosuppressants to progressively taper the corticosteroid dosage. Current research is focused on the use of monoclonal antibodies (mAbs) directed against target molecules involved in the pathogenesis of PG. However, available data on their efficacy are based on sporadic case reports and clinical experiences, so the authors aimed to evaluate the efficacy of risankizumab, an anti-interleukin-23 mAb, in the management of two complex PG cases...
May 1, 2024: Advances in Skin & Wound Care